Alvise Berti

Prof. Alvise Berti


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
FMFrancesco Menzella
Francesco Menzella
RCRory Chan
Rory Chan
ABAlvise Berti
Alvise Berti
MMMaria RIta Marchi
Maria RIta Marchi
MCMarcello Cottini
Marcello Cottini
FBFrancesco Bini
Francesco Bini
Allergic bronchopulmonary aspergillosis (ABPA) is a complex, progressive immune-allergic pulmonary disease that primarily affects patients with underlying predisposing conditions such as severe asthma and cystic fibrosis. Triggered by the non-invasive airway colonization of Aspergillus fumigatus, ABPA drives a hyper-amplified Type-2 and epithelial-mediated inflammatory cascade characterized by extreme elevations in total serum immunoglobulin E (IgE), profound local and systemic eosinophilia, and the formation of tenacious, high-attenuation mucus plugs. Historically, diagnostic recognition has been delayed by overlapping clinical features with severe asthma and atypical presentations mimicking thoracic malignancies, leading to irreversible lung injury. However, the revised 2024 International Society for Human and Animal Mycology (ISHAM) criteria, molecular component-resolved diagnostics, rapid on-site evaluation techniques, and the pheno-endotyping framework proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force now facilitate earlier and more accurate identification during the pre-bronchiectatic serological stage. While systemic corticosteroids, triazole antifungals, and airway clearance techniques remain foundational for acute exacerbations, targeted monoclonal antibodies—including anti-IgE, anti-IL-5/IL-5Rα, anti-IL-4Rα, and upstream anti-TSLP agents—have inaugurated a precision medicine paradigm for refractory and steroid-dependent disease. This comprehensive review synthesizes current advances in ABPA immunopathogenesis, diagnostic biomarkers, clinical-radiological phenotyping, and targeted biological strategies, while highlighting ongoing challenges in predictive biomarker validation and individualized biologic sequencing.